Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Oncolytics Biotech Inc.NASDAQ: ONCY
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -CA$438.74M, compared with -CA$484.4M a year earlier.
Context
- Retained earnings amounted to 5376.0% of total assets at the end of Q1 FY2026, up 2917.4 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +9.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
CAD · from the balance sheet
- Latest · FY2025
- (589.32M) CAD
- Year-over-year change
- -23.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (589.32M) | -23.4% |
| FY2024 | 2024-12-31 | (477.71M) | -7.1% |
| FY2023 | 2023-12-31 | (446M) | -6.6% |
| FY2022 | 2022-12-31 | (418.25M) | -6.3% |
| FY2021 | 2021-12-31 | (393.42M) | — |
Retained Earnings vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +9.4% is the highest of 9, against a peer median of -27.9%.
- Retained earnings amounts to 5376.0% of total assets for ONCY, versus a peer median of 424.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$69.17M USD | -44.0% | — | 129.8% | |
| Mar 2026 | -$114.55M USD | -44.0% | — | 119.6% | |
| Mar 2026 | -$316.39M USD | -11.8% | — | 1460.4% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | -$375.44M USD | -44.6% | — | 295.1% |
| Mar 2026 | -CA$438.74M CAD | +9.4% | — | 5376.0% | |
| Mar 2026 | -$654.79M USD | -109.7% | — | 542.5% | |
| Mar 2026 | -$730.69M USD | -6.9% | — | 364.6% | |
| Mar 2026 | -$1.23B USD | -11.3% | — | 484.8% | |
| Mar 2026 | -$1.28B USD | -5.8% | — | 588.0% | |
| Peer median (excluding ONCY) | — | -27.9% | — | 424.7% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41.26M | 11.67M | 34.91M | 15.94M | 7.14M |
| Short-term Investments | 0 | 20.47M | 0 | 0 | 0 |
| Net Receivables | 866K | 521K | 15K | 68K | 786.23K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 980K | 0 |
| Total Current Assets | 44.9M | 35.68M | 38.17M | 18.88M | 9.39M |
| Property, Plant & Equipment (Net) | 976K | 652K | 647K | 1.31M | 1.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 998K | 0 | 0 | 0 |
| Total Non-current Assets | 976K | 1.65M | 647K | 1.31M | 1.01M |
| Total Assets | 45.88M | 37.33M | 38.82M | 20.19M | 10.4M |
| Account Payables | 594K | 2.25M | 1.08M | 1.09M | 4.81M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 408K | 79K | 532K | 1.62M | 3.3M |
| Total Current Liabilities | 2.69M | 3.95M | 4.24M | 6.69M | 8.37M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 6.73M | 6.73M | 6.73M | 6.73M | 6.74M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 7.09M | 6.89M | 7.02M | 7.52M | 7.24M |
| Total Liabilities | 9.78M | 10.83M | 11.26M | 14.2M | 15.62M |
| Common Stock | 391.35M | 404.04M | 430.91M | 438.19M | 0 |
| Retained Earnings | (393.42M) | (418.25M) | (446M) | (477.71M) | (589.32M) |
| Accumulated OCI | 388K | 662K | 544K | 961K | 8.54M |
| Other Stockholders Equity | 3.62M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 36.1M | 26.5M | 27.56M | 5.98M | (5.21M) |
| Total Debt | 655K | 373K | 423K | 1.06M | 772.51K |
| Net Debt | (40.61M) | (11.29M) | (34.49M) | (14.88M) | (6.37M) |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.